Kinnate Biopharma (NASDAQ:KNTE – Get Rating) released its quarterly earnings results on Wednesday. The company reported ($0.72) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.70) by ($0.02), Yahoo Finance reports.
Kinnate Biopharma Stock Down 0.9 %
Shares of NASDAQ:KNTE opened at $5.41 on Friday. The firm has a market cap of $238.96 million, a price-to-earnings ratio of -2.16 and a beta of 0.20. Kinnate Biopharma has a 12 month low of $3.30 and a 12 month high of $15.86. The company’s fifty day simple moving average is $6.19 and its 200 day simple moving average is $8.24.
Institutional Trading of Kinnate Biopharma
Several hedge funds and other institutional investors have recently modified their holdings of the company. Alliancebernstein L.P. bought a new stake in shares of Kinnate Biopharma in the fourth quarter worth $81,000. Jane Street Group LLC bought a new position in shares of Kinnate Biopharma in the 4th quarter valued at about $77,000. SVB Financial Group bought a new stake in Kinnate Biopharma during the fourth quarter worth about $143,000. Squarepoint Ops LLC bought a new position in Kinnate Biopharma in the fourth quarter valued at approximately $153,000. Finally, Marshall Wace LLP raised its stake in shares of Kinnate Biopharma by 30.5% during the 4th quarter. Marshall Wace LLP now owns 14,944 shares of the company’s stock worth $91,000 after purchasing an additional 3,492 shares in the last quarter. Institutional investors and hedge funds own 98.68% of the company’s stock.
Wall Street Analysts Forecast Growth
About Kinnate Biopharma
Kinnate Biopharma Inc, a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; KIN-3248 small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors FGFR2 and FGFR3 genes; and small molecule research programs, including Cyclin-Dependent Kinase 12(CDK12) inhibitor in its KIN004 program.
- Get a free copy of the StockNews.com research report on Kinnate Biopharma (KNTE)
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
- Europe Raises Interest Rates, Should the Fed Follow?
- PacWest Bancorp May Escape a Credit Downgrade After this Happens
- Dollar General Offers Great Prices, but the Stock isn’t a Value
Receive News & Ratings for Kinnate Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kinnate Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.